The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2025 James S. Huston Antibody Science Talent Award Recipient
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • The Antibody Society’s Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures 2025
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

A new career opportunity from Aureka Biotechnologies, Inc.

November 7, 2025 by Joshua Dorai

Aureka Biotechnologies is expanding its Antibody Therapeutics team!

Aureka Bio is seeking a Principal Scientist or Director to lead antibody discovery programs in immunology and metabolic diseases. This role offers an exciting opportunity to contribute to a fast-growing, AI-driven biotech advancing next-generation biologics.

Full Job Description

Role: Principal Scientist or Director, Antibody Therapeutics in Immunology and Metabolic Diseases

Location: Irvine, CA

Company Summary: 

Aureka Biotechnologies is an AI-driven biotech startup integrating high-throughput biology with generative AI to discover and develop antibody therapeutics with exceptional speed and quality. Through multiple pharma partnerships, our platform has been validated to deliver best-in-class, differentiated antibodies that are difficult to identify using traditional approaches.

Position Summary:

Aureka Bio is seeking a highly motivated, passionate, and detail-oriented Senior Scientist or Principal Scientist to join our Antibody Therapeutics team. This is an exciting opportunity to contribute to a fast-growing, AI-driven biotherapeutics company dedicated to rapidly generating next-generation biologics for Immunology & Inflammation (I&I) and metabolic diseases.

The successful candidate will have 6+ years of hands-on experience in protein engineering and immunoscreening techniques, with a strong track record in biotherapeutic discovery and development. This role will provide the opportunity to lead multiple discovery campaigns, advancing programs from concept through preclinical development in close collaboration with cross-functional teams, including bioassay, translational biology, and CMC.

This is a bench-facing, on-site position based in Irvine, CA, offering high visibility and impact within a dynamic and collaborative environment. The final title and level will be determined based on experience.

Key Responsibilities

  • Lead the design, discovery, and optimization of monoclonal, bispecific, and multispecific antibodies using display and screening platforms (B-cell cloning, phage, and yeast display).
  • Execute small- and large-scale antibody expression and purification using chromatography techniques and evaluate purity via SDS-PAGE, analytical SEC, and Western blot.
  • Perform high-throughput antibody screening assays, including binding kinetics, ligand blocking, and epitope binning, to rapidly identify and prioritize lead candidates.
  • Design and develop recombinant protein-based immunoassays to characterize therapeutic antibodies using biochemical and biophysical methods.
  • Co-lead biotherapeutic discovery campaigns and partner closely with in vitro and in vivo pharmacology teams to evaluate PK/PD, efficacy, and safety profiles.
  • Provide strategic and technical input on antibody design, developability, and candidate selection during early-stage development.
  • Interface with CROs and external collaborators to ensure high-quality data generation and timely project execution.
  • Present experimental results and program updates to project teams, senior management, and collaborators.
  • Maintain accurate experimental documentation in ELN and ensure compliance with best data practices.
  • Stay current with emerging literature and technologies relevant to antibody engineering and biologics discovery.

Professional Experience and Qualifications

  • PhD in Biochemistry, Biomedical Engineering, Molecular Biology, or related discipline with at least 6 years research experience working in a biotech or large pharma setting is a must.
  • Experience working in therapeutic antibody pipeline discovery, screening, antibody engineering and optimization is a must.
  • Expertise in designing and conducting in vitro protein-based assays using diverse biophysical and bioanalytical methods (e.g., SPR/BLI, ELISA, DLS, thermal stability, immunoassays) is a must.
  • Strong understanding of protein engineering, Fc modifications, and developability assessments is essential.
  • Ability to work independently and as part of a team in a fast-paced environment with strong analytical and problem-solving skills, with attention to detail is essential.
  • Experience with antibody screening databases and proficiency in data analysis/visualization software, such as Spotfire, Dotmatics, D360, etc. is a plus.
  • Demonstrated scientific innovation and productivity, as evidenced by patents and/or peer-reviewed publications.
  • Strong communication and interpersonal skills, with the ability to present complex data clearly to cross-functional teams, leadership and collaborators.
  • Self-motivated, collaborative, and enthusiastic about contributing to a multidisciplinary, early-stage biotech focused on breakthrough antibody therapeutics.

Compensation:

Competitive and commensurate with experience, including salary, equity, and benefits—aligned with the company’s long-term success.

Why join us:

  • Competitive compensation, comprehensive healthcare coverage, equity participation, family leave and paid time off
  • A dynamic early-stage work environment and highly interdisciplinary, talented team with a collaborative and innovation-driven culture.
  • Participation in an unprecedented opportunity to significantly impact the quality of life of patients by developing a targeted approach to delivering therapeutic molecules.

Professional growth opportunities through mentoring, training, immersion in cross-functional projects, and opportunities to learn and try new things.

Contact Alon Wellner, Chief Innovation Officer at alon@aurekabio.com to apply.

Filed Under: Jobs

Announcing The Antibody Society’s 2025 James S. Huston Antibody Science Talent Award winner!

October 15, 2025 by Joshua Dorai

👏 We are proud to announce Dr. Xin Zhou, Ph.D., as the recipient of the 𝟮𝟬𝟮𝟱 𝗝𝗮𝗺𝗲𝘀 𝗦. 𝗛𝘂𝘀𝘁𝗼𝗻 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗧𝗮𝗹𝗲𝗻𝘁 𝗔𝘄𝗮𝗿𝗱!

Dr. Zhou was selected for her pioneering work in protein engineering and chemical biology, advancing understanding of immune signaling, cancer drug resistance, and therapeutic reprogramming. She will present her research at the upcoming 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 & 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in San Diego this December, and we look forward to her talk.

Dr. Zhou is an Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and of Cancer Biology at Dana-Farber Cancer Institute.

𝗔𝗯𝗼𝘂𝘁 𝗗𝗿. 𝗭𝗵𝗼𝘂 𝗮𝗻𝗱 𝗵𝗲𝗿 𝗹𝗮𝗯:

She holds a Ph.D. in Bioengineering from Stanford University School of Medicine and completed postdoctoral research at University of California, San Francisco as a Merck – Damon Runyon Cancer Research Foundation Fellow. Since joining Dana-Farber and Harvard in 2022, her lab has developed technologies in protein engineering and chemical biology to study cancer and immune signaling, drug resistance, and metastasis, and to engineer self-regulated antibodies, enzymes, and cells for therapeutic reprogramming.

𝗛𝗲𝗿 𝗺𝗮𝗻𝘆 𝗵𝗼𝗻𝗼𝗿𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲:

V Foundation Women Scientists Innovation Award for Cancer Research, NIH Director’s New Innovator Award (DP2), Damon Runyon Dale F. Frey Award for Breakthrough Scientists, Helen Gurley Brown Foundation Trailblazer Award, Dana-Farber Innovations Therapeutic Accelerator LEAP Award, MIT Technology Review Innovators Under 35 (China region), PEGS Protein & Antibody Engineering Summit Young Scientist Keynote Award, and the NIH K99/R00 Pathway to Independence Award.

𝗠𝗮𝗻𝘆 𝗰𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗗𝗿. 𝗭𝗵𝗼𝘂 𝗼𝗻 𝘁𝗵𝗶𝘀 𝘄𝗲𝗹𝗹 𝗱𝗲𝘀𝗲𝗿𝘃𝗲𝗱 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻! 🏆

If you are an early-career scientist interested in participating in next year’s award, you can learn more about the submission guidelines.

Filed Under: Huston Award

Precision in Antibody Format Design – Webinar with Dotmatics & BioGlyph.

October 6, 2025 by Joshua Dorai

In next generation antibody discovery, precision is everything. Even small oversights can cascade through workflows, compromising data and decisions.

Join experts from Dotmatics and BioGlyph in a webinar hosted by The Antibody Society to explore how precision from sequence design to data integration can transform antibody R&D.

We’ll highlight how platforms like Luma and BioGlyph tackle challenges in data fidelity, workflow integration, and early error detection, helping scientists make smarter, faster decisions.

𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀:

  • Fernando Garces, Ph.D. – CEO, BioGlyph
  • Christian Olsen, Ph.D. – VP, Strategy, Protein Therapeutics, Dotmatics

𝗗𝗮𝘁𝗲: October 16, 2025 | 𝗧𝗶𝗺𝗲: 12:00 PM EDT / 9:00 AM PDT

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: https://events.teams.microsoft.com/event/293844e7-fe36-4d3e-9b06-aab3652ebd0f@7384e819-4d00-4994-9c4a-b036004b889f

A𝗱𝗱 𝘁𝗵𝗶𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿: https://mcusercontent.com/281543b4b89e8ab3d8438030b/files/f33ea104-7356-3ae4-d9ea-8a6ae3a1bb33/Upcoming_Webinar_Dotmatics_amp_TAbS_team_up_to_discuss_Unprecedented_Precision_in_Antibody_Format_Design_Oct16_2025.ics

Filed Under: Ab news

Join Tabs and the AIRR-C for the First TAbS Townhall!

October 2, 2025 by Lorissa Corrie

TAbS is excited to welcome you to the very first Townhall Meeting on October 15, 2025! 🎉 Join the event on Zoom using this LINK as they share the latest updates about the organization, highlight new and ongoing programs, and introduce the committees and resources available to members. This will also be a great opportunity for committee members to connect and get to know one another ahead of the upcoming programmatic year.

Can’t make it live? No problem! The session will be recorded! Don’t forget to share this invitation with fellow antibody enthusiasts who may want to join in.

Filed Under: AIRR Community, The Antibody Society Tagged With: Adaptive Immune Receptor Repertoire Community, Meetings, The Antibody Society

The Antibody Society (TAbS) Call for Abstracts at AET San Diego 2025 | Dec 14-17

September 26, 2025 by Joshua Dorai

Are you a 𝘀𝘁𝘂𝗱𝗲𝗻𝘁, 𝗽𝗼𝘀𝘁𝗱𝗼𝗰, or 𝗲𝗮𝗿𝗹𝘆 𝗰𝗮𝗿𝗲𝗲𝗿 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 working in academia, biotech, or pharma? If your research is antibody-focused, this is your chance to share it with a global community of scientists and industry leaders.

We’re excited to invite abstract submissions for this year’s 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 & 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 (𝗔𝗘𝗧) 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in San Diego, taking place December 14-17, 2025.

Selection Criteria

  • All abstracts will be reviewed by our judges and 10 participants will be selected.

  • Selected participants will have the chance to present their poster at AET San Diego 2025.

  • Each selected participant will receive 1 complimentary full-conference pass.

Details to include in your submission

  • Conference title: AET San Diego

  • Title of your research topic

  • Name(s) of author(s)

  • Relevant industry/academic affiliations

  • Abstract (maximum half a page)

𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝘁𝗼 𝘀𝘂𝗯𝗺𝗶𝘁: October 22, 2025

𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗲𝗿𝗲: https://docs.google.com/forms/d/e/1FAIpQLSfael-7rtpiNTxT8t2QX63WhVhJSeQ-NkyOvfC70nc1xEWw2g/viewform

𝗣𝗹𝗲𝗮𝘀𝗲 𝗻𝗼𝘁𝗲: Travel and accommodation are not included, and this opportunity is open only to those who are not already registered attendees.

𝗧𝗔𝗯𝗦 𝗺𝗲𝗺𝗯𝗲𝗿𝘀, you are very welcome to share this within your networks so we can reach as many promising researchers as possible.

We look forward to receiving your abstracts!

The Antibody Society | Informa Connect Life Sciences

Filed Under: AET Basel: Call For Abstracts!

Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • A new career opportunity from Aureka Biotechnologies, Inc. November 7, 2025
  • Announcing The Antibody Society’s 2025 James S. Huston Antibody Science Talent Award winner! October 15, 2025
  • Precision in Antibody Format Design – Webinar with Dotmatics & BioGlyph. October 6, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals